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Abstract
Background: Ovarian Hyperstimulation Syndrome (OHSS) is a severe health complication observed in
some patients undergoing hormonal stimulation during IVF. Presence of OHSS is often associated with a
high count of growing follicles responding to FSH hyperstimulation. However, the number of responding
follicles may not be sufficient enough to predict the onset and severity of OHSS. The aim of this study was
to find whether follicular fluid (FF) and serum concentrations of Inhibin A and Inhibin B in patients
undergoing IVF treatment may serve as a predictor of OHSS status independent of the growing follicles
count.
Methods: Serum and follicular fluid of fifty-three women undertaking the IVF program were separated
into four groups according to their OHSS status and growing follicles count and analyzed for serum and
FF concentrations of Inhibin A and Inhibin B. The resulting data were combined with clinical and
demographic data to calculate indices independent of the growing follicles count.
Results: Serum Inhibin A and Inhibin B concentrations showed no significant difference between the
severe OHSS group and the control group without OHSS. Moreover, the serum concentrations of Inhibin
A and Inhibin B were strongly correlated with the growing follicles count. Their concentrations in the high
responders group (>18 follicles) were significantly higher (p < 0.00001, p < 0.0001) when compared with
normal and low responders (<18 follicles). To suppress the dependence on the growing follicle count,
three indices were constructed and calculated. The best association with OHSS status and independence
of the growing follicle count was achieved by using the Inhibin B TFF/SBM index calculated as follows:
[concentration in FF] × [growing follicle count]/[concentration in serum] × [body mass]. The Inhibin B TFF/
SBM index showed a clear difference (p = 0,00433) between the group with severe OHSS and the control
group, while showing no apparent correlation with the growing follicle count.
Conclusion: These observations demonstrated that while neither serum nor FF concentrations of Inhibin
A nor Inhibin B can be used as an OHSS predictor independent of the growing follicle count, calculated
indices may meet the criteria.
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Ovarian Hyperstimulation Syndrome (OHSS) is a severe
health complication observed in the luteal phase of some
patients undergoing hormonal stimulation during the IVF
cycle [1]. The syndrome is characterized by an increase in
size of the ovaries associated with a dramatic increase in
vascular permeability causing ascites and eventually more
severe complications [2,3]. The severe form of OHSS,
characterized by haemoconcentration, thrombosis, oligu-
ria, dysponea and tachycardia [3,4] requires patient hos-
pitalization and constitutes a potentially lethal
complication of infertility treatment for otherwise healthy
women [5].
Embryo transfer and the resulting pregnancy have a nega-
tive impact on the severity of OHSS, so in the case of
increased risk of the development of the severe or even
critical form of OHSS, the embryo transfer is often can-
celled and embryos have to be cryo-preserved. However,
cryopreservation of all embryos is not a preferred method
by infertility physicians [6]. An accurate and reliable
OHSS prediction tool is thus needed.
However, our knowledge of OHSS pathogenesis is far
from complete and predictive factors of OHSS are not effi-
cient enough. The only common denominator in OHSS
pathology is the role of hormonal hyperstimulation by
FSH or Clomifene citrate followed by hCG administration
(a common substitute of natural LH in IVF cycles), which
is considered a triggering factor of OHSS. In FSH-stimu-
lated ovaries, a peak of hCG may cause a hypersensitive
response resulting in complications as described above
[7]. The potential OHSS biomarkers should be thus
expected among proteins and small molecules synthe-
sized and/or modified in the ovary in response to FSH and
hCG administration.
Several candidates have been proposed as potential
biomarkers of OHSS, e.g. VEGF and VEGF receptor [8],
Inhibin [9], AMH [10,11]. However, some of these poten-
tial biomarkers (Inhibin B, AMH) may predict OHSS
because they predict the number of responding follicles.
Enskog et al [9] took into account the relation between
potential biomarkers and matched the OHSS patients and
the controls in age and follicle count. The number of
responding follicles showed poor predictive value in sev-
eral other studies [2,3].
To test a potential association with OHSS status, several
proteins involved in FSH signaling in ovarian follicles
(PAPP-A, IGFBP4, IGF-1, Inhibin A, Inhibin B) have been
tested in preliminary experiments. Based on the results of
preliminary experiments, two proteins secreted by ovarian
granulosa cells in response to FSH stimulation  Inhibin A
and Inhibin B [12] have been chosen.
Inhibin secretion by granulosa cells and the evidence that
ovarian Inhibin A and Inhibin B suppress FSH production
has been reported by Ericsson and Hsueh [13]. Inhibins
are heterodimeric glycoprotein hormones composed of
one α (18 kDa) and one β (14 kDa) chain linked by disul-
phide bonds. Inhibin A consists of α-βα subunits and
Inhibin B consists of α-ββ subunits [14]. Meunier et al.
[15] reported the expression of Inhibin subunits in vari-
ous tissues, the Inhibin α subunit, however, is predomi-
nantly expressed in the gonads.
The aim of our present study was to find whether FF and
serum concentrations of Inhibin A and Inhibin B in
patients undergoing IVF treatment are correlated with the
presence or absence of OHSS and how are those parame-
ters related to the number of responding ovarian follicles.
FF and serum concentrations of Inhibin A and Inhibin B
were analyzed in IVF patients with a high ovarian
response (>18 follicles) with respect to the OHSS status.
Samples were collected at the time of the oocyte retrieval.
Concentrations of Inhibin A and Inhibin B in paired FF
and serum samples were also used in combination with
clinical and demographic data to calculate indices which
were evaluated as independent parameters.
Methods
Female patients
Patients undergoing regular stimulation for IVF were
recruited for the study at the Centre of Assisted Reproduc-
tion, Dept. of Obstetrics and Gynecology, General Teach-
ing Hospital in Prague. A total of 376 women were
recruited for the study between March 2006 and October
2007. Samples of patients who did not agree with blood
drawing or failed to deliver a good quality serum and/or
follicular fluid sample were not selected for Inhibin A and
Inhibin B analysis.
Patients were separated into four groups based on the
number of growing follicles and OHSS status. Groups des-
ignated OHSS-2 and OHSS-3 included patients with a
high number of growing follicles (the number of growing
follicles ranged from 18 to 57 follicles). Patients in group
OHSS-2 suffered from moderate OHSS and patients in
group OHSS 3 showed symptoms of severe OHSS. No
patient suffering from a critical form of OHSS was
observed during the study, so no such sample is included.
Patients for the control OHSS-1 (>18 follicles) group were
selected to match the parameters of OHSS 3 group (Age
2434 years old, average number of growing follicles =
29.1, mean BMI = 22.3) as closely as possible. Patients in
the other control group (OHSS-1, <18 follicles) included
patients with a growing follicle count ranging from 6 to
18. Those patients were also selected to match the param-
eters (age and BMI) of OHSS 3 group.Page 2 of 7
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in individual patients and the OHSS status was evaluated
(without any patient intervention and Inhibin analysis) in
a cohort of 567 consecutive patients collected in 2007
(January to December).
Follicular fluid and serum samples were obtained with the
patient's permission. All the patients participating in this
study signed an Institutional Board approved Informed
Consent form.
All subjects underwent a standard treatment protocol
FSH ovarian hyperstimulation using GnRH long agonists
or GnRH short antagonist's protocol with hCG induction
of the follicular/egg maturation 36 hours before the col-
lection of the egg. Optimal FSH dose was chosen individ-
ually according to the antral follicle count and growing
follicle monitoring.
Growing follicle count
The number and size of follicles responding to FSH stim-
ulation was regularly monitored by transvaginal sonogra-
phy measurements. The growing follicle count used in
this study was obtained at the day of oocyte pickup and
includes all follicles > 12 mm.
OHSS classification
Patients were classified by using the criteria of Navot et al
[2] and separated into 3 groups. For the purpose of this
study, patients with mild OHSS were not analyzed sepa-
rately and the control groups (OHSS 1) contained both
patients without symptoms of OHSS as well as patients
with mild OHSS. The moderate OHSS group (OHSS 2)
was characterized by abdominal distention and discom-
fort, nausea, ascites and ovarian size > 5 cm (determined
by sonography). Patients with severe OHSS (OHSS 3
group) were characterized by massive ascites, haemocon-
centration (hematocrit >45%, WBC > 15000/μl), oliguria,
creatinine >130 μmol/l, creatinine clearance < 50 ml/min
and enlarged ovaries.
Follicular fluid aspiration and blood processing
FF was obtained from the puncture of ovarian follicles (14
to 22 mm in diameter). After the oocytes were removed,
the FF was pooled, cleared by centrifugation, and the
resulting supernatant was transferred into sterile tubes,
frozen at -20°C and stored at -70°C for further analysis.
Samples of FF visibly contaminated with blood were
excluded from the study. In parallel, samples of blood (5
ml) were taken on the day of oocyte retrieval, allowed to
clot, cleared by centrifugation, and the resulting sera were
frozen at -20°C and kept at -70°C until assayed.
Immunoassays
Serum and FF concentrations of Inhibin A and Inhibin B
were analyzed using ELISA kits (DSL, A Beckman Coulter
Company, Webster, TX, USA). The immunodiagnostic
kits were processed according to the manufacturer's
instructions. For the analysis of FF Inhibin A and Inhibin
B, the FF samples were diluted 200-fold with calf plasma
(Scantibodies Laboratory, Inc., Santee, CA, USA). The lin-
earity of the dilution was verified (recovery percentages
obtained within the range of 84.6% to 109%).
Statistical analysis
The concentration data and the calculated indices in each
group were expressed as arithmetic mean +/- SD. The
resulting data were tested for statistical significance using
the Mann-Whitney U test and the statistical significance
was set at p < 0,05. Data were processed using the NCSS
2007 software (Number Cruncher Statistical Systems,
Kayswille, UT, USA).
Results
OHSS and growing follicle count
The relation between the number of responding follicles
in individual patients and the OHSS status was evaluated
in a cohort of 567 consecutive patients collected in 2007
(Table 1). The patients were separated into three groups
based on the growing follicle count. The low responders'
group was characterized by less than 6 responding folli-
cles, in the group of normal responders, the growing folli-
cle count ranged from 6 to 18 follicles and patients with a
growing follicle count above 18 were considered high
responders. Among the total of 567 patients, 13 patients
with severe OHSS (OHSS 3 group) have been found, and
the majority (11) of them was present within the group of
Table 1: Distribution of 567 consecutive patients into low, normal and high responder groups
Low responders (<6 follicles) (%) Normal responders (618 follicles) 
(%)
High responders (>18 follicles) 
(%)
Total (%)
n  Total 137 (100) 305 (100) 125 (100) 567 (100)
n  OHSS 1 137 (100) 299 (98) 103 (83.4) 539 (95.1)
n  OHSS 2 0 4 (1.3) 11 (8.8) 15 (2.6)
n  OHSS 3 0 2 (0.7) 11 (8.8) 13 (2.3)
n = number of patients
The count and percentages of patients based on OHSS status were calculated in each responder group independentlyPage 3 of 7
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OHSS 3 patients constitute less than 1% of patients.
Inhibin A and Inhibin B levels
The presented data clearly demonstrate that in a group of
high responders, the growing follicle count is only a weak
indicator of OHSS status. To obtain an additional predic-
tive marker of OHSS independent of the growing follicle
count, paired samples of follicular fluid (FF) and blood
serum (drawn on the day of oocyte retrieval) were ana-
lyzed for Inhibin A and Inhibin B concentrations. In the
first experiment, only the data of patients with no or mild
OHSS status (OHSS 1) were analyzed. The group of nor-
mal responders (618 growing follicles) was compared
with the data of high responders  Table 2.
The serum concentrations of both Inhibin A and Inhibin
B were significantly different in both groups (p < 0.00001
for Inhibin A and p < 0.0001 for Inhibin B). That observa-
tion clearly demonstrates a dependence of serum Inhibin
A and Inhibin B concentrations on the growing follicle
count.
Calculated indices
To compensate for the effect of a growing follicle count
and to obtain independent parameters, three indices were
constructed and calculated. One Follicle Contribution
(OFC) index simply divides the serum concentration with
the growing follicle count.
OFC-BM index is calculated in a similar way, but also con-
siders the patient body mass.
A different philosophy was used to calculate the TFF/SBM
index. The index reflects a distribution of total inhibin
between FF and blood and is calculated as follows:
The constructed indices have shown no significant differ-
ence between the high responder and normal responder
groups, so the same analysis was performed as a retrospec-
tive study in the groups suffering a moderate (OHSS 2)
and severe (OHSS 3) form of OHSS  Table 3.
Both the Inhibin A OFC-BM and TFF/SBM indices can dis-
tinguish the OHSS 3 group from the control group and
also from the OHSS 2 group at the p < 0.05 level. Better
significance was achieved by using the Inhibin B TFF/SBM
index. Inhibin B TFF/SBM index can distinguish the OHSS
3 group from the control group at p < 0.01 and the OHSS
3 from the OHSS 2 group at p < 0.05.
Although the Inhibin A OFC-BM and TFF/SBM indices
may be also useful as severe OHSS indicators, the Inhibin
B TFF/SBM index is particularly promising as an OHSS
indicator independent of the growing follicle count.
Inhibin B TFF/SBM index combines a highly significant
difference between the severe OHSS group and the control
group with no apparent correlation with the growing fol-
licle count.
Discussion
In the present retrospective study, FF and serum concen-
trations of Inhibin A and Inhibin B were analyzed with
respect to OHSS status in patients undergoing regular IVF
treatment. In contrast to most studies where the basal
serum levels of Inhibin B on Day 3 to Day 5 are correlated
with the expected ovarian response and IVF outcome [16-
20], our present study is one of the few analyzing levels of
OFC = [ ( / )] /[ ]serum concentration pg mL growing follicle count
OFC - BM = ×[ ( / )] [ ( )] /[serum concentration pg mL body mass kg growing follicle count]
TFF/SBM = ×[ ( / )] [FF concentration pg mL growing follicle count] /[ ( / )] [ ( )]serum concentration pg mL body mass kg×
Table 2: Serum and FF concentrations and calculated indices in high responders (>18 follicles) and normal and low responder groups 
(<18 follicles)
OHSS 1, >18 follicles
(n = 18)
OHSS 1, <18 follicles
(n = 18)
Number of Follicles 31.6 ± 9,72 10.6 ± 2,76* 6
Inhibin A FF [pg/mL] 52536 ± 15184 42350 ± 13137
Inhibin A Serum [pg/mL] 405 ± 125 155 ± 98.5 * 5
Inhibin B FF [pg/mL] 60960 ± 24105 45923 ± 15689
Inhibin B Serum [pg/mL] 288 ± 141 109 ± 66.3 * 4
Calculated Indices
Inh A OFC 13.7 ± 5.87 14.9 ± 7.90
Inhibin A OFC-BM 884 ± 334 947 ± 500
Inhibin A TFF/SBM 64.9 ± 24.8 49.8 ± 16.2
Inh B OFC 9.45 ± 4.56 11.5 ± 9.79
Inhibin B OFC-BM 619 ± 302 729 ± 601
Inhibin B TFF/SBM 111 ± 48.5 121 ± 119
Presented data are arithmetic means ± standard deviations
Significance: *4 p < 0.0001; *5 p < 0.00001; *6 p < 0.000001Page 4 of 7
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FF and serum concentrations in paired samples are
required to calculate the TFF/SBM index and the paired FF
and serum samples can only be obtained at the day of
oocyte retrieval. The use of paired samples is a useful tool
to study ovarian hormones. For instance, it has been dem-
onstrated that the amount of FF Inhibin A is correlated
with its serum concentration in paired samples [21], an
observation confirming the hypothesis that the ovary is a
principal source of inhibin A in serum of non-pregnant
women [22].
Some of the potential biomarkers of OHSS, namely
Inhibin B and Anti Muellerian Hormone (AMH), can pre-
dict the OHSS status because they are good indicators of
ovarian response to FSH stimulation and can thus predict
the number of responding follicles [16,23,24]. The grow-
ing follicle count is, in turn, correlated with the OHSS sta-
tus, since the high number of growing follicles is a
necessary prerequisite to OHSS development [25,26].
Enskog et al [9] has monitored the serum levels of Inhibin
A and Inhibin B from the beginning of ovarian stimula-
tion until 3 days post embryo transfer. They observed a
higher Inhibin B concentration in the OHSS group during
the gonadotropin stimulation and also at the day of
oocyte retrieval. Inhibin A was found to be elevated only
after the OHSS onset. Our present study has only partially
confirmed those observations. We have found that both
serum Inhibin A and Inhibin B was elevated in the OHSS
group at the day of oocyte retrieval, but that only Inhibin
A was elevated significantly. Moreover, Inhibin A serum
concentration depends on the FF volume [21,27] which is
a function of a growing follicle count. Babayof et al [28]
was studying the difference between hCG and GnRH ago-
nists in triggering the oocyte maturation in IVF patients
with polycystic ovaries. They also reported that elevated
serum Inhibin A levels during the luteal phase are associ-
ated with a higher risk of OHSS in the hCG group. How-
ever, only four patients with OHSS were reported in the
hCG group, so the possible association of severe OHSS
with elevated serum Inhibin A remains uncertain.
Considering these observations and our own results, we
have found that the serum concentration of inhibins is
not a very reliable predictor of OHSS. FF concentrations of
both Inhibin A and Inhibin B were in agreement with pre-
vious reports [29,30], but did not show any clear associa-
tion with OHSS status.
Due to the observations described above, we decided to
combine FF and serum concentrations and other clinical
data to eliminate the effect of a variable number of grow-
ing follicles and to obtain an independent OHSS predic-
tor.
To calculate the contribution of a single follicle to the
serum inhibin concentration (OFC index) was an obvious
strategy, but brought only moderate improvement over
the serum concentration data. When the patient's body
weight was also considered and used to calculate the OFC-
BM index, the effect of body mass was only moderate. This
observation is not very surprising, since controversial
reports showing the correlation of body weight and/or
BMI with OHSS status are available [3,31,32].
The best result has been obtained by using TFF/SBM
index, particularly with the Inhibin B TFF/SBM index.
Table 3: Serum and FF concentrations and calculated indices in OHSS 1, OHSS 2 and OHSS 3 groups
OHSS 3, >18 follicles (n = 10) OHSS 2, >18 follicles (n = 7) OHSS 1, >18 follicles (n = 18)
Number of Follicles 29.1 ± 5.17a4 37.8 ± 10.2 31.6 ± 9.72
Inhibin A FF [pg/mL] 49236 ± 14388 49172 ± 15688 52536 ± 15184
Inhibin A Serum [pg/mL] 553 ± 222 456 ± 155 405 ± 125
Inhibin B FF [pg/mL] 46082 ± 19025 55383 ± 25435 60960 ± 24105
Inhibin B Serum [pg/mL] 373 ± 185 391 ± 199 288 ± 141
Calculated Indices
Inhibin A OFC 18.9 ± 7.29 12.8 ± 5.95 13.7 ± 5.87
Inhibin A OFC-BM 1158 ± 346*,a 749 ± 332 884 ± 334
Inhibin A TFF/SBM 44.2 ± 12.2 *,a 71.8 ± 24.7 64.9 ± 24.8
Inhibin B OFC 12.70 ± 5.66 10.6 ± 5.78 9.45 ± 4.56
Inhibin B OFC-BM 807 ± 395 616 ± 315 619 ± 302
Inhibin B TFF/SBM 62.0 ± 23.8* 2, a 96.9 ± 35.3 111 ± 48.5
Presented data are arithmetic means ± standard deviations.
Significance between OHSS1 and OHSS 3 groups: *p < 0.05; * 2p < 0.01.
Significance between OHSS 1 and OHSS 2 groups: ap < 0.05, a4p < 0.0001.Page 5 of 7
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of FF inhibin and serum inhibin concentration multiplied
by body mass. The total amount of FF inhibin was esti-
mated by using the growing follicle count. The more accu-
rate result would probably be obtained by using the total
FF volume instead of the growing follicle count [21], but
from a practical point of view, obtaining the growing fol-
licle count appears to be more convenient in a daily labo-
ratory routine than the total FF volume measurement.
Moreover, the use of the growing follicle count provides
sufficient results.
The differences in OHSS predictive value between Inhibin
A and Inhibin B were probably due to the fact that their
serum concentrations display a different time course dur-
ing the menstrual cycle [33]. While Inhibin B increases
gradually following the FSH stimulation of the granulosa
cells and is already declining at the time of oocyte
retrieval, Inhibin A is only elevated at the time of the LH
surge and stays high even after the time of oocyte pickup.
In this respect, our observations are in accordance with
those reported by Enskog et al [9].
During the 20 months of recruitment, 10 complete FF and
serum samples of OHSS 3 patients and 7 samples of
OHSS 2 patients were collected. The number of OHSS 3
and OHSS 2 samples is too low to perform a more
detailed statistical analysis and we are not able to collect a
sufficient amount of samples in a reasonable timeframe.
The result of this study should be thus considered as a pre-
liminary work. A larger, preferably multicentric study is
needed to confirm our observations.
Conclusion
The observations presented in this study demonstrate that
both serum and FF concentrations of Inhibin A and
Inhibin B have no or only weak association with OHSS
status. Moreover, Inhibin A and Inhibin B serum concen-
trations are strongly correlated with the growing follicle
count and thus cannot be considered as a reliable OHSS
biomarker. All the calculated indices appear to be better
indicators of OHSS status than serum and FF inhibin con-
centrations. Inhibin B TFF/SBM index is a particularly
promising candidate. It combines the highly significant
difference between the severe OHSS group and the control
group, while showing no apparent correlation with the
growing follicle count. Due to the low number of OHSS 3
and OHSS 2 (10 and 7 respectively) samples collected
during the 20 months of recruitment, the data should be
considered as preliminary.
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